April 10, 2023
1 min read
Save
Celanese’s drug delivery platform to be used with iDose TR
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
Key takeaways:
- Celanese and Glaukos entered into an agreement for the VitalDose drug delivery platform to be used with the iDose TR.
- VitalDose has the potential to provide continuous dosing.
Celanese has entered into an agreement with Glaukos to supply the VitalDose drug delivery platform for Glaukos’ iDose TR, according to a press release.
The iDose TR is a microinvasive intraocular implant designed to continuously deliver a travoprost formulation to lower IOP in those with primary open-angle glaucoma or ocular hypertension. VitalDose has the potential to help provide continuous dosing, which can reduce issues with patient compliance and adherence.
Image: Adobe Stock
According to the release, VitalDose provides “reliable, controlled-release performance and has a long history of use in approved parenteral drug products in the United States and Europe.”
Glaukos submitted a new drug application for iDose earlier this year.
Published by:
Read more about
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.